Skip to main content

Table 4 Number of patients with deteriorating BILAG activities from baseline

From: Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

BILAG body system (N = 14)a 6 weeksb 10 weeks 18 weeks
General 0 (0 %) 0 (0 %) 0 (0 %)
Mucocutaneous 0 (0 %) 0 (0 %) 0 (0 %)
Neurological 0 (0 %) 0 (0 %) 0 (0 %)
Musculoskeletal 0 (0 %) 0 (0 %) 0 (0 %)
CV/Respiratory 0 (0 %) 0 (0 %) 1 (7 %)
Vasculitis 0 (0 %) 0 (0 %) 0 (0 %)
Renal 0 (0 %) 1 (7 %) 0 (0 %)
Hematology 1 (7 %) 1 (7 %) 2 (14%)
Overallc 1 (7 %) 2 (14%) 3 (21%)
  1. aN = total number of patients. bTwenty-four hours after fourth infusion. cAs applied to any BILAG body system.